Clinical trials have shown that the expression of HHLA2 in hepatoma cells is closely related to the presence of CD8+ T cells in tumors and predicts good prognosis, suggesting the potential of HHLA2 as a therapeutic target for HCC treatment [127]. Here, HHLA2 is linked to hepatocellular carcinoma.